$144 Million is the total value of Aisling Capital LLC's 5 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Q | Sell | Quintiles Transnatio Hldgs I | $58,600,000 | -30.7% | 1,153,773 | -36.7% | 40.72% | -21.2% |
| DRTX | Sell | Durata Therapeutics, Inc. | $40,800,000 | +2.0% | 3,030,175 | -3.2% | 28.35% | +16.0% |
| Exit | MEI Pharma, Inc. | $0 | – | -770,000 | -100.0% | -3.79% | – | |
| ICPT | Exit | Intercept Pharmaceuticals | $0 | – | -137,519 | -100.0% | -5.75% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.